## Utah Department of Health TB Control & Refugee Health Program

**Workplace Contact Investigation Protocols** 

July 2006

## TABLE OF CONTENTS

A.	INTRODUCTION	1
В.	DEFINITIONS	2
C.	WOKPLACE CONTACT INVESTIGATION ACTION PLAN	3
D.	PROCESS OF A WORKPLACE CONTACT INVESTIGATION (WCI)	
	Step 1 – Medical Records Review and Patient Interview	5
	Step 2 - Assess Need for WCI and Determine Its Scope	5
	Step 3 – Establish Communication with the Worksite	6
	Step 4 – Develop a Written Action Plan	7
	Step 5 – Conduct an Environmental Evaluation of the Worksite	7
	Step 6 – Develop the Contact List	7
	Step 7 – Arrange for Follow-up X-Rays	8
	Step 8 – Arrange for Screenings and TSTs	8
	Step 9 – Educate the Company Employees About TB	9
	Step 10 – Notify Contacts and Conduct Screening(s)	9
	Step 11 – Decide Whether to Expand or Limit the Contact Investigation	.11
	Step 12 – Conduct a Three-Month Follow-up Screening If Needed	.11
	Step 13 – Report the Initial Results	.12
E	ACKNOWLEDGEMENTS	12

APPENDIX B – Sample forms, letters, and additional tools	18
Forms	
Index Patient Schedule	19
Symptom History for Establishing TB Infectious Period	
Contact Investigation Record	
Medical History for TB Screening	22
SLVHD TB Reactor Form	23
<u>Letters</u>	
From company to employees re suspect case + testing dates	24
Enclosure for letter: documentation of eval from private physician	
From LHD to employees re: confirmed case + testing dates	
School Letter: from LHD to ALL Parents/Staff	27
School Letter: from LHD to Staff/Parents of Students with Exposure w/Test Dates.	28
School Letter: from LHD to Staff/Parents of Students w/Exposure – 2nd TST date	29
Miscellaneous	
Internal Notification of a Public Health Incident	30
Employer Acknowledgment of Confidentiality	31
Chest X-ray Log	
Contact Investigation Summary Report	33
Concentric Circle Approach to Contact Investigations for TB	34
Workplace Contact Investigation – Action Plan	

#### A. INTRODUCTION

The following guidelines were primarily developed to assist local health departments (LHDs) in completing contact investigations in the workplace. However, occupational health and infection control staff outside of health departments may find this document useful. Suspect and confirmed cases of tuberculosis are of public health concern and are immediately reportable to the Utah Department of Health (UDOH) TB Control Program or to the local health departments as required by the Utah Communicable Disease Rule, R386-702, which can be accessed at <a href="www.rules.utah.gov/publicat/code/r386/r386-702.htm">www.rules.utah.gov/publicat/code/r386/r386-702.htm</a>. For information on policies, protocols, and recommendations for the State of Utah on how to manage a suspected or confirmed TB case, please consult the LHD Nursing Supervisor, the Nurse Consultant at the UDOH TB Control Program, and/or the TB Control Program Manual at <a href="www.health.utah.gov/cdc/tbrefugee">www.health.utah.gov/cdc/tbrefugee</a>.

Worksite contact investigations (WCIs) may be appropriate for confirmed/suspected cases of <a href="mailto:sputum">sputum</a> AFB-smear positive pulmonary and/or laryngeal TB, which are considered to be infectious. WCIs are generally not indicated for cases of confirmed or suspected sputum AFB-smear negative or extrapulmonary TB. Although the steps outlined in the guidelines need not be followed in the sequence presented, the case manager should ensure that each step is addressed during the course of the contact investigation. All steps are to be implemented by the case manager unless otherwise indicated.

When conducting a WCI, it is critical to identify and screen all employees whose proximity to and interactions with the index case place them at risk for TB exposure and infection. Whether a given employee is at risk largely depends on three factors:

- 1. **Quantity of exposure**: How much time was spent sharing air with the index case during the infectious period? The key measure is the number of hours of shared air that is, the number of hours the employee was exposed face-to-face to index case.\*
- 2. **Quality of exposure**: How conducive is the shared environment to TB transmission?
- 3. **Employee characteristics**: Does the employee have HIV infection or other preexisting health problems that place him/her at high risk for TB infection if exposed or of developing TB disease if they are infected?

The contacts are prioritized based on their exposure time and personal level of risk of developing TB disease. The first round of testing involves administering tuberculin skin tests (TSTs) to the high priority contacts. If no positive TSTs are found or if the percentage of individuals testing positive is below the percentage expected to be found in that community, expanding the contact investigation is not necessary. TSTs are repeated 8 to 10 weeks after the infectious period ends to make sure no transmission occurred; and the results are re-evaluated to determine whether to expand or limit the WCI.

\_

<sup>\*</sup> In cases involving high-risk contacts, the number of hours of exposure to the index case may include the amount of time spent in rooms that were occupied by the index case up to 2 hours previously.

When a WCI is conducted, the health department and the employer share responsibility for its success. The health department is responsible for:

- 1. determining the size, scope and flow of investigation
- 2. educating employer/managers about TB, contact investigations, and procedures for establishing risk of infection
- 3. educating employees about TB infection and disease
- 4. ensuring that contacts are tested for TB infection and, if necessary, referred for further screening and treatment
- 5. maintaining confidentiality.

The employer is responsible for:

- 1. providing a safe working environment
- 2. maintaining confidentiality
- 3. cooperating with the health department
- 4. releasing employees without penalty for testing, including chest x-rays (CXRs) and other follow-up appointments.

#### **B. DEFINITIONS**

For the purpose of this guideline, the following definitions apply:

Concentric circle approach: A means of grouping contacts into higher or lower priorities. A contact investigation should begin by testing high priority contacts. If the investigation documents evidence of transmission, it may be expanded to include lower priority contacts.

Contacts: A person who has shared air with the index case.

High priority contacts: Either close contacts or high-risk contacts.

Close contacts: Contacts having the greatest number of hours of shared air with the index case. Since TB is rarely transmitted by a short exposure, a close contact is an individual who has 12 or more hours of exposure within a 15-foot radius within a small number of days or as determined on a case-by-case basis.

High-risk contacts: Contacts at high risk of developing TB disease if infected, including children less than 4 years of age, individuals infected with HIV, and individuals with the following medical conditions: silicosis, gastrectomy or jejunoileal bypass, low body weight (10% or more below ideal), chronic renal failure/dialysis, diabetes mellitus, organ transplant, carcinoma of head or neck, or high-dose corticosteroid therapy (greater than or equal to 15 mg/d for one month or greater). These individuals are considered high priority contacts even if the number of hours of shared air is low.

*Index case*: A suspected or confirmed case of pulmonary or laryngeal TB. *Low priority contacts*: Contacts who are not high risk or who have fewer hours of shared air with the index case.

*Non-contact*: A person who has probably not shared air with the index case but requests inclusion in the contact investigation, i.e. a worried person who was probably not exposed.

Secondary TB case: A case of active TB disease discovered as a result of the contact investigation.

#### C. WORKSITE CONTACT INVESTIGATION – ACTION PLAN

STEP	ACTIVITY/DESCRIPTION	RESPONSIBLE	DUE	DATE
		PERSON	DATE	COMPLETED
STEP 1	MEDICAL RECORDS REVIEW AND PATIENT INTE	RVIEW		•
1-A	Review the index case's medical information to			
	confirm diagnosis of sputum AFB-smear positive pulmonary and/or laryngeal TB.			
1-B	Interview the index case.			
, _				
1-C	Establish the period of infectiousness.			
1-D	Determine if there are factors present at			
	worksite that enhance likelihood of TB			
	transmission.			
STEP 2	ASSESS NEED FOR WCI AND DETERMINE ITS SC	OPE		
2-A	Decide if a WCI is necessary.			
2-B	Review current policies regarding			
	confidentiality.			
2-C	Re-interview index case, focusing on worksite;			
	request permission to disclose her/her identity.			
STEP 3	ESTABLISH COMMUNICATION WITH THE WORKS	SITE		
3-A	Contact the worksite.			
3-B	Establish who will be the employer liaison.			
3-C	Provide educational information re: TB and			
	contact investigations to the employer			
	representative and other key staff.			
3-D	Determine who will pay for the different			
	investigation costs.			
3-E	Ensure that the employer understands the need			
2.5	for confidentiality and other legal concerns.			1
3-F	Answer any questions re: the index case that			
3-G	the employer may have.  If applicable, establish media contacts at			
3-6	UDOH, the LHD, and at the worksite.			
STEP 4	DEVELOP AN ACTION PLAN			
4-A	Verify information provided by the index case	I		1
7-7	with the employer			
4-B	Prepare a written action plan.			
4-C	If applicable, document the need and			1
	arrangements for the screening in a letter to the			
	company.			
STEP 5	CONDUCT AN ENVIRONMENTAL EVALUATION O	F THE WORKSITE		

A	D-1	
5-A	Determine where the index case spent time.	
5-B	Evaluate the spaces to determine how	
	conducive they are to TB transmission.	
STEP 6	DEVELOP THE CONTACT LIST	
6-A	Identify individuals with whom the index case had contact.	
6-B	Determine which employees are high priority vs low priority contacts.	
6-C	Prepare a roster of contacts.	
6-D	Identify contacts who face barriers to healthcare.	
STEP 7	ARRANGE FOR FOLLOW-UP X-RAYS	
7-A	Identify a resource for chest x-rays (CXRs).	
7-B	Determine who will pay for the CXRs.	
STEP 8	ARRANGE FOR SCREENINGS AND TSTS	
8-A	Determine with the employer a screening site.	
8-B	, ,	
0-В	ON-SITE SCREENING: Select a suitable space, date, and time for the screenings.	
8-C	OFF-SITE SCREENING: Determine where	
0-0	employees will be referred for testing.	
8-D	Set a target date for the completion of the first	
	round of screening.	
STEP 9	EDUCATE THE COMPANY'S EMPLOYEES ABOUT	ТВ
9-A	Assess what kinds of educational materials	
	would be appropriate.	
9-B	With the employer, plan and conduct the educational session.	
9-C	If an educational session is not feasible, make	
	alternative arrangements for distributing	
	materials and answering employees' questions.	
STEP 10	NOTIFY CONTACTS ABOUT AND CONDUCT SCRI	EENING SESSION(S)
10-A	Notify affected employees regarding their exposure and need for screening.	
10-B	ON-SITE TESTING: Conduct initial screening	
10-8	activities.	
10-C	OFF-SITE TESTING: Await test results.	
10-D	Arrange for and obtain CXRs.	
10-E	Refer for bacteriology evaluation and	
	consideration for treatment.	
10-F	Be diligent in follow-up to make sure that	
	referred individuals are properly diagnosed and treated.	
STEP 11	DECIDE WHETHER TO EXPAND OR LIMIT THE WO	
11-A	Evaluate initial screening results to determine	
'''	whether to expand the WCI.	
11-B	Consult with Local Health supervisor/officer.	
STEP 12	CONDUCT A THREE-MONTH FOLLOW-UP SCREE	NING-
12-A	Notify contact who need to be re-tested.	
40.5	Make a list of contacts who require follow-up	
12-B		
	testing and set follow-up testing date.	
12-C	testing and set follow-up testing date.  Conduct follow-up testing.	
12-C 12-D	Conduct follow-up testing.  Arrange follow-up CXRs as necessary.	
12-C 12-D STEP 13	Conduct follow-up testing.  Arrange follow-up CXRs as necessary.  REPORT THE INITIAL RESULTS	
12-C 12-D	Conduct follow-up testing.  Arrange follow-up CXRs as necessary.	

#### D. PROCESS OF A WORKPLACE CONTACT INVESTIGATION

The steps outlined below describe the activities that need to be completed in order to conduct a successful worksite contact investigation. Although the steps outlined in the guidelines need not be followed in the sequence presented, the case manager should ensure that each step is addressed during the course of the contact investigation. The forms associated with a particular step are listed in brackets and hyperlinked; more detailed information on implementing steps can be found in Appendix A and can be accessed by clicking on the light bulb icons.

#### STEP 1 - Medical Records Review and Patient Interview

A) Strive to gather as much information as possible on a case prior to contacting an employer. Review the index case's medical information to **confirm the diagnosis/strong suspicion of active sputum AFB-smear positive pulmonary and/or laryngeal TB**. Remember that a positive PPD alone does not indicate disease. Worksite contact investigations are generally not indicated for cases of confirmed/suspect sputum AFB-smear negative or extrapulmonary TB.

#### B) **Interview the index case** to determine:

- when symptoms, particularly coughing, first became apparent
- patient's pattern of activities during period of infectiousness
- with whom the patient habitually had contact at work, while commuting, at school, and at any other location during the period of infectiousness.

The interview is also a time to educate patients about TB and to address their concerns.

[Symptoms History Form] [Index Patient Schedule Form]

- C) Establish the period of infectiousness using information from the patient interview and the medical record.
  - Determine, based on treatment records, whether the period of infectiousness is over or is ongoing. [Symptoms History Form]
- D) Based on the index case interview, make an initial determination as to whether there are factors present that enhance the likelihood of TB transmission at the worksite, such as:
  - type of worksite (eg, an enclosed environment)
  - type of work (eg, the index case works closely with several co-workers)
  - type of people present in the worksite (eg, children, the elderly, HIV-positive individuals, or other at-risk persons).

#### STEP 2 – Assess Need for Worksite Contact Investigation & Determine Its Scope

A) Consult with the Local Health Department (LHD) supervisor/officer and TB Controller to **decide if a worksite contact investigation (WCI) is needed**, and if so, to make a preliminary determination of its scope and scale. If it is determined that a WCI is

necessary, **consider alerting other involved agencies** of the case and its likely amount of media interest. [Internal\_Notification\_Form].

- B) **Review current policies regarding confidentiality** in UCA 26.6 and the TB Rule and prepare appropriate documentation to share with the index case and worksite representatives. [Employer\_Confidentiality\_Acknowledgment]
- C) **Re-interview index case**, focusing on questions related to the worksite. Explain the importance of the WCI and his/her legal protections but request permission to disclose the patient's identity to the employer. In some circumstances, public health officials may legally reveal the index case's identity, but the patient's cooperation usually improves the process and helps to eliminate gossip and hearsay.

#### STEP 3 – Establish Communication with the Worksite

- A) **Contact the worksite.** A phone call to the human resources manager is a good place to start for assistance in identifying the most appropriate contact person. It is important to gain the cooperation of management as they can be invaluable in planning and carrying out the WCI.
- B) Establish who will be the employer's representative/liaison; this should be a person who has appropriate decision-making authority.
  - Review confidentiality laws/policies in UCA 26.6 and the TB Rule prior to revealing index case identity. [Employer\_Confidentiality\_Acknowledgment]
  - Emphasize that the identity of the index case should only be revealed on a "need to know" basis.
- C) Provide educational information to the employer representative and other key staff, including unions, to provide information regarding TB. Discuss the need for a WCI and how it will be conducted, including the mechanism for identifying contacts. Establish a clear understanding of the roles and responsibilities of the health department and the employer. Distribute suitable educational materials.
- D) **Discuss the costs** that will be incurred and explore whether the employer's workers compensation policy or health insurer may be able to cover all or part of the costs. The employer and the LHD should arrive at an understanding as to who will pay for TSTs, CXRs, sputa collection, and the initial evaluation. Refer to the Utah TB Control Program Manual for guidance on evaluating contacts; the Manual is available on the Internet at <a href="https://www.health.utah.gov/cdc/tbrefugee/program manual.htm">www.health.utah.gov/cdc/tbrefugee/program manual.htm</a>.
- E) **Discuss the employer's legal responsibility** in connection with the WCI. This includes the need to maintain confidentiality of the index case and others who may be found to have latent TB infection (LTBI) or active TB disease (ATBD); the employer's obligation to provide a safe working environment; and the employer's responsibility to ensure that an individual diagnosed with active TB does not suffer any negative

repercussion at the worksite or by other employees as stipulated by the Americans with Disabilities Act.

- F) **Discuss the index case** and address the employer's concerns regarding his/her absence from work. Explore the possibilities of using
  - paid leave
  - short-term disability
  - incentives and enablers.
- G) **Discuss media issues**. If applicable, inform your Public Information Officer (PIO) of the WCI and keep him/her updated. Establish media contacts at the state and local health departments and at the worksite. [Internal\_Notification\_Form]

# <u>STEP 4 – Develop a Written Action Plan (with employer liaison & LHD Supervisor/Officer)</u>

- A) Consult with the employer liaison to verify information provided by the patient regarding worksite locations, activities, and contacts. [Index Patient Schedule Form] Note and explore discrepancies.
- B) Prepare an action plan. [Action Plan]
- C) If indicated, **send an official letter** to the company, school, or facility to document the need to have employees screened and to verify the arrangements made to conduct screening.

#### STEP 5 – Conduct an Environmental Evaluation of the Worksite

- A) **Confirm where the index case spent time**, including lunchrooms, break rooms, and commute vehicles. [Index\_Patient\_Schedule\_Form]
- B) Evaluate the spaces in question to determine how conducive they are to TB transmission. Determine the airflow of the spaces, i.e. where the air comes from and where it goes.

#### **STEP 6** – Develop the Contact List

A) Examine the index case's activity patterns at the worksite and **identify individuals** with whom he/she came into contact. Keep in mind that this is a fluid process; self-reporters should be interviewed and classified accordingly.

[Index Patient Schedule Form]

- B) Determine which employees are high priority, low priority contacts, or non**contacts.** Refer to the definitions of these terms in Section B. [Concentric Circle Approach]
- C) Prepare a roster of contacts. [Contact\_Investigation\_Record]
- D) Identify contacts who face barriers to healthcare, e.g. language barriers, lack of insurance and/or transportation.

#### **STEP 7– Arrange For Follow-Up X-Rays**

- A) Identify a resource for chest x-rays (CXRs). It is necessary to perform CXRs to rule out active pulmonary TB under the following conditions:
  - a contact is found through the investigation to be skin test positive (∃5 mm), including a person who reports a previously positive TST
  - a contact is symptomatic (has a cough that has persisted for three weeks or more plus one other symptom of TB) regardless of the TST result
  - a contact is immune-compromised, younger than 4 years of age, or there is doubt as to whether the TST would be effective or accurate for this person.
- B) As with the cost of TSTs, explore options with the employer about who will pay for the CXRs. The employer's workers compensation policy or health insurer may be able to cover part or all of the cost. Contact the State TB Control Program if any pediatric (<18 years) CXRs are required.

#### STEP 8 - Arrange for Screening and TSTs

- A) **Determine with the employer the screening site.** On-site screening makes obtaining a TST more convenient for employees, and testing can be performed efficiently and promptly in a few sessions.
- B) ON-SITE SCREENING: Consult with the employer liaison to select a space, dates, and times at which health staff will be present on-site to interview the contacts, administer the TST, and read and explain the test results. If this cannot be accomplished in a private and confidential manner, consider administering the TSTs and arrange to conduct counseling on another date.
- C) OFF-SITE SCREENING: Determine where employees will be referred for testing.
  - Make arrangements with off-site providers, including instructions for reporting test results and information on how billing and payment will be handled. Have employees sign a Release of Information form.

[Private Physician TST and Screening]

- Establish referral and follow-up procedures for public and private treatment of both ATBD and LTBI. Collect data to ensure all contacts are screened and that individuals with positive results are treated.
  - [Private\_Physician\_TST\_and\_Screening] [Contact\_Investigation\_Record].
- Notify off-site providers of the date by which all results should be reported to the health department. Follow-up with off-site providers if you do not receive test results reports when they are required.
- D) **Set a target date for the completion of the first round** of screening, whether this is performed on-site or off-site.

#### Step 9 – Educate the Company's Employees About TB

- A) Education may be the most important part of a worksite contact investigation and should be provided to affected employees at the worksite. Providing facts and answering questions can help to reduce unnecessary fears and help employees to be more willing to cooperate with the investigation. **Assess what kinds of educational materials would be appropriate** for the employees, given their literacy levels, English-language skills, and other relevant factors. You may need materials of more than one kind in order to reach everyone in your audience. The TB Education and Training Resources website, www.findtbresources.org/scripts/index.cfm, is an excellent resource.
- B) With the employer liaison, **plan and conduct the educational session(s).** Obtain permission for employees to be away from their duties in order to attend. Ensuring the presence of adequate translation and interpreting services is the responsibility of the employer and/or LHD, not the employee, per Title VI of the Civil Rights Act of 1964 (<a href="www.hhs.gov/ocr/lep/">www.hhs.gov/ocr/lep/</a>). A list of Medicaid funded interpreters can be found at <a href="www.health.state.ut.us/medicaid/pdfs/interpreter.pdf">www.health.state.ut.us/medicaid/pdfs/interpreter.pdf</a>; interpreting services can also be found in the yellow pages under "Translators & Interpreters." Hand out written materials at the literacy level and in a language appropriate to employees, and provide a telephone number that employees can call if they want more information.
- C) If an educational session is not feasible, **make alternative arrangements** for distributing educational materials and answering employees' questions.

#### **Step 10** – Notify Contacts and Conduct the Screening

- A) **Notify affected employees** that they have been exposed to an individual with TB and need to be tested for possible TB infection. In most instances, the employer will inform the affected employees in person. A letter may be used in some circumstances, e.g. to inform contacts who are no longer employed at the worksite. Whatever the method:
  - include suitable supporting information for enclosure in letters and distribution during in-person notifications

 establish a phone number, liaison, or other means for handling employee requests for further information.

[Letter Company to Employees] [Letter LHD to Employees] [Letter\_LHD\_to\_All\_Parents\_and\_Staff] [Letter\_LHD\_to\_Affected\_Parents\_and\_Staff]

Whatever method you use, it is helpful to follow-up the notification with an educational session. Your goal is to encourage the contacts to comply with the screening instructions, while avoiding rumors and unnecessary fears.  $\bigcirc$ 

- B) **ON-SITE TESTING: Conduct initial screening activities.** For each individual who arrives for screening:
  - verify the person's information in the contact roster
  - take a **medical history** [Medical\_History\_for\_TB\_Screening]
  - explain the TST procedure
  - administer the TST.

Remember that privacy and confidentiality are essential as each contact must be asked about personal health information, including but not limited to symptoms, previous TST results, and HIV status. Separate, self-contained offices are preferable, but screening can also be done in somewhat isolated work cubicles if privacy and confidentiality can be maintained. Using some type of background sound (a radio or sound generator) can mask the conversations, while curtaining the cubicle entrance can provide visual privacy.

Instruct the tested individuals to return for the scheduled reading of the tests 48-72 hours after placement. At that time, you will **read the tests**, explain the results, and answer any concerns/questions.

C) **OFF-SITE TESTING:** If contacts are referred to clinics or off-site providers, your task at this stage is to **await the test results**. Record the date, results, and provider of each contact's TST on the contact roster as the info is received. [Contact Investigation Record] Follow up as needed with employees and providers to make sure that the testing takes place and results are reported in a timely manner.

#### D) AFTER ALL SCREENING: Arrange for and obtain CXRs for:

- individuals with positive TST results
- anyone who shows TB symptoms regardless of test results
- HIV-positive individuals for whom there is reason to believe that the skin test result is ineffective.

[Chest Xray Log]

- E) If any individuals have findings indicative of TB infection or disease, **refer for bacteriology evaluation and consideration for treatment**.
- F) **Be diligent in follow-up** to make sure that referred individuals are properly diagnosed and treated. The investigation is not complete until all testing has been accomplished and the final outcomes of all treatment individuals have been documented.

#### Step 11 – Decide Whether to Expand or Limit the Contact Investigation

A) Evaluate the initial screening results to determine whether to expand the WCI. The decision to expand the WCI should be made on a case-by-case basis.

<u>Limiting the WCI</u>: When the screening has yielded no evidence of TB transmission – that is, there were no secondary cases of TB disease, no skin test conversions in contacts at the worksite, and/or the percentage of positive tests falls below the community's baseline positivity rate – consider limiting the worksite investigation to the people already tested. To expand testing at this point probably would not be productive.

Expanding the WCI: Indicators for expanding the investigation would be:

- identification of secondary TB cases, especially if it can be linked by evidence or transmission or by DNA fingerprinting
- a skin test conversion in a workplace contact
- rate of positive TSTs significantly exceeds the baseline positivity rate for a population that has similar demographic and geographic characteristics as the group you tested.

If the screening yields such results, hold a second round of testing that brings in the contacts who were placed in the next ring on the Concentric Circle Diagram. Continue the investigation until the screening yields the rate of positive tests than you would expect to find if random testing were done in your community.

B) If the screening results are higher than anticipated, **consult with the Local Health supervisor/officer** or, if needed, contact the UDOH TB Control Program for further assistance.

#### Step 12 – Conduct a Three-Month Follow-Up Screening If Needed

- A) **Notify contacts** who need to be re-tested to explain why the retesting is important and inform them about the arrangements. [Letter LHD to Parents and Staff 2nd TST]
- B) Make a list of contacts who require follow-up testing and determine an appropriate date to conduct the testing 8 to 10 weeks after the initial TST or last known exposure date while index case was infectious.
- C) Conduct follow-up TSTs to ensure that all skin test converters have been identified.
- D) **Arrange** follow-up CXRs as necessary.

#### **Step 13 – Report the Initial Results**

# A) Prepare an aggregate or summary report and present it to the employer, indicating:

- how many persons were screened
- how many positive and negative test results were obtained
- whether any secondary cases of TB disease were found
- whether any of the secondary cases were infectious.

Specifics of the additional TB cases should be discussed with the employer only in the event that further screening efforts are required. Submit a copy of this report to the TB Controller. [Contact\_Investigation\_Summary\_Report]

#### E. ACKNOWLEDGEMENTS

These guidelines were adapted from the Francis J Curry National TB Center's *Toolbox: Contact Investigation in a Worksite* and from forms/letters provided by the Salt Lake Valley Health Department.

#### **APPENDIX** A – Additional information in implementing steps in the guidelines.

#### **Step 1A – Medical Records Review**

Formatted

Review the medical record to determine whether the patient has been infectious and, if so:

- Determine site of TB disease
- Review TST and chest x-ray results
- Review sputum smear, culture, and/or NAA testing results
- Determine when symptoms were first present
- Determine where the patient was seen for medical care in the past year, and how many times the patient has been to a doctor, clinic, or hospital in the past year

#### Step 1B - Interview the Index Case

The patient interview is one of the most critical parts of a contact investigation. For the patient interview to be successful, the health worker should:

- Develop rapport with the patient
- Assess the patient's knowledge, feelings, and beliefs about TB; educate the patient; and address their concerns
- Explain the importance of the CI in preventing and controlling TB
- Ask open-ended questions
- Relate onset of symptoms to certain events, e.g. birthdays, holidays, major new reports, and discuss medical care sought for symptoms.
- Discuss confidentiality

Formatted

**Formatted** 

#### Step 1C - Establish the period of infectiousness

Using information obtained from the medical records review and the patient interview:

Formatted Formatted

Formatted

- Determine, as closely as possible, the date when symptoms began.
- Compare the date when symptoms began to the date when the first positive finding consistent with TB disease (CXR, positive sputum smear) was identified.
- Estimate the start of infectiousness period based on these dates.

#### Step 1D – Determine if factors enhancing transmission exist at worksite

Answer these questions about the worksite:

- Where does the index case work? Inside or outside?
- If inside, what kind of space does he/she work in? Enclosed or open? Obtain a description of the area, including size of room, sunlight, ventilation.
- How many people work in the same space?
- In addition to employees in the index case's workspace, how many other employees does he/she spend time with at work? Obtain a description of these areas.
- With whom and where does the index case eat lunch/spend breaks? Obtain a description of these areas.
- With whom and how does the index case get to and from work?

#### Step 2A – Assess need for WCI and determine its scope

Review data gathered from the patient interview and answer these questions:

- Does the worksite have factors that enhance TB transmission?
- How many people need to be tested?
- Who are the people who need to be tested?
- Is media likely to be interested or aware?

#### Step 2C – Reinterview index case

See "How to" Steps 1B and 1D.

#### **Step 3A – Contact the worksite**

Answer these questions about the worksite:

- Does the worksite have an employee health department or nurse?
- Who is the patient's supervisor?
- Is there a union representative?

**Formatted** 

#### Step 3C – Discuss WCI with employer representatives

Cover the following topics in discussions with the employer:

- What TB is, how it is diagnosed and treated, LTBI vs ATBD
- Mechanism for identifying potential contacts.

#### **Step 3D – Discuss costs**

Arrive at an understanding about who will pay for the following:

- Notification letters
- Education, including interpretive and translation services
- Testing and chest x-rays
- Follow-up and medication

**Formatted** 

#### Step 5B – Evaluating the work spaces in question

In order to assess who in the workplace is at risk, it is important to understand what kind of environment the worksite provides. If possible, contact the facility manager or environmental engineer for assistance. Use your best judgment on the likelihood of TB transmission in each work area.

Formatted

#### Step 6A – Identify individuals with whom the index case came into contact.

Answer these questions:

- What are the index case's principle job responsibilities and activities?
- What is the index case's work schedule (days and times)? Were there any changes to the work schedule within the period of infectiousness?
- How much time has the index case spent in the workplace during the infectious period?
- Did the index case stay in one work area for the entire shift, move about the building(s) regularly, or leave the premises for extended periods?
- Which employees, if any, share the workspace of the index case? What is the proximity of their work areas?
- In an average day or week, which other employees does the index case spend time with during the course of his or her activities: meetings, visits to other persons' workspaces, commuting, lunch and break times?

#### Step 6C – Prepare a contact roster

**Formatted** 

With employer liaison, prepare a **list of contacts** that includes the following information:

- Name
- Date of birth or age
- Gender
- Contact information (address and phone number)
- Relationship to index case
- Risk of developing TB disease if infected (high/low)
- Dates of possible exposure (to determine need for re-screening)

#### Step 8B – Onsite Screening

Consult with employer liaison to **select a space** that can be set up to accommodate the screening efficiently. Privacy and confidentiality are essential as each contact must be asked about personal health information, including symptoms, previous TST results, and HIV status. The space must be private enough for the contact to respond candidly. Separate, self-contained offices are preferable, but screening can also be done in somewhat isolated work cubicles if privacy and confidentiality can be maintained. Using some type of background noise, e.g. a radio or generator, can mask the conversations between the health worker and the employee; and curtaining the cubicle entrance can provide visual privacy.

Formatted

#### Step 9B – Plan educational session.

Your educational efforts should address the following topics:

- What TB is, how infection occurs, and how it is diagnosed and treated.
- LTBI vs ATBD
- The need to screen co-workers due to the recent discovery of a TB case at the worksite (maintain the confidentiality of the index case)
- The degree of risk faced by worksite contacts (Concentric Circle Approach). The degree of risk faced by families of worksite contacts.
- The purpose of the contact investigation and how the testing will be carried out (describe the TST procedure).
- Follow-up that will occur in the event that a test is positive.
- Confidentiality.

#### Step 9C - Make alternative arrangements to educational sessions.

These arrangements may include:

- providing materials for distribution during in-person notifications
- including materials with letters of notification
- establishing a phone number of liaison to handle employee requests for further information (See Step 10B)

#### Step 10A – Notify affected employees re: their exposure to an active TB case.

The options to notify affected employees include:

- a form letter or personalized letter from the employer, distributed on-site or by mail
- a form letter or personalized letter form the health department, distributed on-site or by mail
- a telephone call
- face-to-face notification by supervisors
- a meeting or educational session
- a combination of these methods.

To determine which options is most suitable, consider such factors as:

- the number of individuals to be notified
- their level of trust for the employer or for the health dept
- their literacy and language skills
- the need to reach contacts who are no longer employed by or connected with the worksite.

Select a signatory (employer or health dept) and **prepare a letter to contacts** which can be mailed as the primary form of notification or distributed during in-person notifications. The letter should document:

- the schedule and procedure for testing and reading of results
- what test results may mean to an individual
- the means by which a private physician can report results to the health dept.

The letter may be useful in reaching contacts no longer connected to the worksite.

Include suitable supporting information for enclosure in letters and distribution during inperson notifications.

#### **Step 10B – Conducting Initial Screening Activities**

Screening activities include asking questions about exposures and risk factors, administering the TST, and reading the results. Unnecessary testing of non-contacts can be avoided by explaining that the initial testing is limited to close contacts. If indicated, non-contacts and/or low priority contacts can be referred to the LHD to obtain TSTs for a fee.

Keeping careful records and completing follow-up of off-site test results is crucial. Even if most of the testing is done on-site, there are likely to be some off-site tests due to unexpected absences, a person's preference for a familiar provider, or other reasons. The investigation is not complete until all results have been reported – and acted upon – if treatment is indicated.

#### ON-SITE TESTING

Bring the supplies needed to carry out the testing. You will want to bring enough materials on hand to test 110% of the identified contacts – that is, be prepared for 10% more individuals than you actually anticipate testing. Avoid unnecessary testing of non-contacts.

**Set up the space** for screening. It is best to arrive 30 minutes prior to the advertised testing times in order to set up.

#### Step 11A – Decide Whether to Expand or Limit the Contact Investigation

**Formatted** 

**Formatted** 

Calculate Baseline Positivity Rate: In any population, a certain percentage of individuals will test positive for LTBI. This percentage is known as the <u>baseline</u> positivity rate and is calculated by the formula:

Formatted

# of newly-identified (+) TSTs x 100 total # of TSTs placed & read.

For example, in the winter of 2002-03, 38 of the 271 TSTs that were placed and read at the Overflow Homeless Shelter were positive. The baseline positivity rate for the homeless in Salt Lake City was calculated as:  $38 \times 100/271 = 14\%$ . The baseline positivity rate of one group will differ from the rates of other groups that have different demographic and geographic characteristics.

To determine LTBI prevalence you can expect locally, look at large, broad-based numbers from TB screenings in your community, such as school screenings, preemployment physicals, and other routine testing. Workplaces that involve childcare, healthcare, or prisoners are likely to have consistently recorded pre-employment test results. What percentage of these tests was positive? This baseline information gives you a rate against which to measure the results of your contact investigation.

Obtain the results of any broad-based local TB screenings of populations that share demographic characteristics with the contacts who are the subjects of your investigation and calculate the baseline positivity rate.

**Formatted** 

Compute the percentage of positive tests, if any, yielded by your WCI using the formula above and compare that number to the baseline positivity rate for guidance on limiting or expanding the investigation.

**Step 13 – Prepare an aggregate report.** A summary report is also a good way to close the WCI with the employer. The employer is not entitled to know the results of the individual employees' tests. Even w/aggregate information, be sure to protect the identity and confidentiality of any individual who tested positive or who is diagnosed as a secondary case of TB. For example, if there are very few women in the screened population, do not provide statistics by sex. Similarly, if few foreign-born individuals were screened, do not detail their results separately from those of the native-born. Protecting the individual is the responsibility of the health workers.

#### **APPENDIX B** – Sample forms, letters and additional tools

#### **FORMS**

Index Patient Schedule Symptom History for Establishing TB Infectious Period Contact Investigation Record Medical History for TB Screening SLVHD TB Reactor Form

#### **LETTERS**

From company to employees re suspect case + testing dates

Enclosure for letter: documentation of eval from private physician

From LHD to employees re confirmed case + testing dates

School Letter: from LHD to ALL Parents/Staff

School Letter: from LHD to Staff/Parents of Students with Exposure w/Test Dates School Letter: from LHD to Staff/Parents of Students w/Exposure – 2nd TST date

#### **MISCELLANEOUS**

Internal Notification of a Public Health Incident
Employer Acknowledgment of Confidentiality
Chest X-ray Log
Contact Investigation Summary Report
Concentric Circle Approach to Contact Investigations for TB
Workplace Contact Investigation – Action Plan

# schedules

# **INDEX PATIENT SCHEDULE**

Index Patient's Name:	Likely Period of Infection	ousness:
	•	
Employer:	Index Patient's Job Title:	Last Day Worked:

Patient Data	As reported by patient	As reported by Employer	Explain discrepancies (if any)
Job description/activities			
Length of service in current position	years and months	years and months	
A. Dates			
Work days/hours	SMTWRFS am/pm to am/pm	SMTWRFS am/pm to am/pm	
B. Dates			
Work days/hours	SMTWRFS am/pm to am/pm	SMTWRFS am/pm to am/pm	
C. Dates			
Work days/hours	SMTWRFS am/pm to am/pm	SMTWRFS am/pm to am/pm	
Group workspaces in which the index patient spent time			
Congregate settings in which the index patient spent time other than normal work routine, e.g. orientations, meetings, etc			
Areas in which the index patient spent lunch and breaks (eg smoking)			
Does patient interact with clients? If so, how?			
Patient's commute			

# SYMPTOM HISTORY FOR ESTABLISHING TB INFECTIOUS PERIOD

Patient's name:					
Date of birth:		_ Cas	se Number <sub>-</sub>		
			1 1	Onset	1
Symptom	YES	NO	Duration	Date	Comments
					Productive/dry:
Cough					
Cough with blood					
Weight loss					
Night sweats					
Chest pain					
Loss of appetite					
Fever					
Chills					
Other					
Infectious period fro (10 weeks prior to syn with TB - which ever i	nptom ons				st positive finding* consiste
Comments:					
Со	mpleted by	/ date	:		/
Tel	lephone nu	mber:			

<sup>\*</sup>Positive findings consistent with TB include, but are not limited to, the following: specimen collected which suggests or confirms a diagnosis of TB (positive AFB smear, positive NAAT for *M.tb*, positive *M.tb* culture), or chest x-ray showing abnormality consistent with TB, or initiation of treatment for TB

### **UDOH Tuberculosis Control Program**

## **Contact Investigation Record**

Case Name	County	PHN	Date case reported D	ate CI started
Disease Site: P / EP / Both	Smear: + / - / not done	Culture: + / - / not done	e Infectious period from	to

Contact	Exposure	HIV/IC	Contact	Date Last	PPD	Results	X-1	Ray	Dx	Tx	Tx Stop	Finish Tx/
	Site	(Y/N) Type*		Infectious Exposure	Initial	Retest	Date	Date Results		Start Date	Date	Reason Not Finished‡
Name DOB	Home Work		HP MP		Date	Date			LTBI			Yes
Relationship Address/Phone#	School Other		LP NC		mm	mm			ATBD			No:
Name DOB	Home Work		HP MP		Date	Date			LTBI			Yes
Relationship Address/Phone#	School Other		LP NC		mm	mm			ATBD			No:
Name	Home		HP		Date	Date			LTBI			Yes
DOB Relationship Address/Phone#	Work School Other		MP LP NC		mm	mm			ATBD			No:
Name DOB	Home Work		HP MP		Date	Date			LTBI			Yes
Relationship Address/Phone#	School Other		LP NC		mm	mm			ATBD			No:
Name DOB	Home Work		HP MP		Date	Date			LTBI			Yes
Relationship Address/Phone#	School Other		LP NC		mm	mm			ATBD			No:
Name DOB	Home Work		HP MP		Date	Date			LTBI			Yes
Relationship Address/Phone#	School Other		LP NC		mm	mm			ATBD			No:

#### \* CONTACT TYPE

HP=high priority contacts are household contacts, contacts <4 yrs, contacts with medical risk (including HIV infection), contacts in congregate setting, or contacts with prolonged exposure MP=medium priority contacts are contacts 5-15 yrs or contacts with medium exposure to index case

**LP**=low priority contacts are all other contacts

NC=a person who probably did not share with the index case but requests inclusion in the CI

# ‡ REASONS FOR NON-COMPLETION OF LTBI TX: 1 - Death 4 - Adverse Effect of Medicine

Exposure Site

- 2 Contact Moved
  3 ATBD Developed
  6 Contact Lost to Follow-up
- 7 Provider Decision

Fax to June/Jerry, UDOH TB Control Program, at (801)538-9913 at 30 days, 120 days, and end of TLTBI

# Medical History for TB Screening

Name	Date of Birth _		_ Date	_
Date of this skin test	Reading	mm Where placed		_
Case No				
HAVE YOU EVER HAD:			<u>CIRCLI</u>	E ONE:
Previous skin test for TB			Yes	No
If yes: When	Where	Results		110
2. Previous CXR	,, nore		Yes	No
2. Previous CXR  If yes: When	Where			
<ol><li>Medicine (curative) for T</li></ol>	B or (preventive) for a po	sitive skin test	Yes	No
If yes: When	Where			
<ol><li>BCG vaccination: What a</li></ol>	ge		Yes	No
<ol><li>Known exposure to some</li></ol>	one with TB		Yes	No
If yes: Who	When	Where		
6. Diabetes			Yes	No
7. Epilepsy 8. Stomach surgery			Yes	No No
9. Lung problems				No
10. Hepatitis A or B? (jaundi				No
11. HIV	ee of fiver problems)		Yes	No
12. Steroids or cortisone			Yes	No
13. History IV drug use				No
14. Other chronic conditions:				No
DO YOU NOW HAVE:  1. Chronic cough: If yes, how 2. Blood in sputum				No No
				NO
3. Loss of appetite				N
4. Weight loss				No
5. Shortness of breath			Yes	No
6. Fever			Yes	No
7. Night sweats			Yes	No
8. Fatigue			Yes	No
9. Do you drink alcohol (liquo	r) everyday?		Yes	No
10. Do you smoke?				No
If yes, how much			*7	No
11. Do you take any medicines				No
If yes, list them:				110
12. Allergies				No
•				110
If yes, list them:				
FOR WOMEN ONLY: Are you	pregnant?Yes	No EDC	i	
Interviewer signature:				
Date / Initials:				
Discussed significant Discussed Signifi	ce of positive PPD			
2 Discussed the need f	for INIL ahamanranhulawi	if indicated		
2 Discussed the fleed i	or mari enemopropriylaxi	o ii muicateu		

	DS#				F	Tu or Referra	bero	culosis Salt Lake	Eval Valle	uation y Health	For Dep	<i>m</i> artmen	it	14		S #:		
-	Co	ommur	nicable	Disea	se Bure	au: Me	dical	Office; 61	0 So :	200 E, F	Rm 20	9, SLC	, UT 84111	(801) 53	4-460	0		
D	ate: /	1		Refer	ring Nur	se/Staff	:					c	linic / Corre	ctions				distriction of the last of the
_	lient's Name	-								AKA:								
	ome Address:		(1.0	nat)			£1	First)	City:			S	tate:	Zip	:		-	
	ome Phone:									Reaso	n fo	r Tes	t?					
	ork Phone:									Employ	men	t:		_ Worl	( Hou	rs:		
)	ate of Birth:												SS#:				-	
7.7	эх:		[], F	emale	[ ]					Out of	ace: (	try in n	Country) ast few yea	ar(s): Y	es []	Nol 1.	-	-
_	octor's name octor's Phone	_							-	When:		пу птр	Where:					
	r. address:								_	Lang	uag	e (s): _			Race	:		
										Emerg	geno	y Con	tact Person					-
	edicaid Yes (		. Prov	ider:		•			_	Relatio	ency	Conta	ct add:	ione				_
-	edical Insura		None	Yes	Positive	Nac	ative	mm		ated Date:	NAME AND ADDRESS OF THE OWNER, WHEN	CANCEL PROPERTY OF PERSONS	MANAGEMENT OF STREET, SALES	Where				
÷	evious TB skin te urrent skin test	est	No	Yes	Positive	-	ative	mm		Read:				2 Step Pi	anned		Yes	T
	st Chest X-ra	v: Wi			J	1		/hen:				sults:						
-				ACCULATION SAN									- Name of Street, Associated			Tv		61.
ŕ	Cough	Yes	No	Starte	d:		Desc	ription of Co	ough:	Colo			Producti			Yes		No
1	Weight Loss	Yes	No	Starte	d:		How	many pound	ds tost?	1? 1		lbs. Normal		l Weig	ht	_	1	
)	Appetite Loss	Yes	s No	Starte	d:			Fever(s	)	Yes		No	C	hills		Ye	S	N
	Fatigue	Yes	s No	Starte	sd:		1	Night Swe	ats	Yes		No Shortne		s of bre	ath	Ye	s N	N
1	Chest Pain	Yes	s No		ed:		C	ontact to	TB?	Yes		Unk	When / Who?					
	Previous TB			Yes		ТВ	Medici	ine:			Hov	w long?		Where	?	r vertrag	1,49	(et)
	Previous TB Current Med Pregnant Chronic illness of	lcation Yes	No M	Yes	No	M.Period	Medici	Medica	ation	Allergie	How	w long?	-	where	rovi		Yes	1
	Current Med Pregnant	lcation Yes	No M	Yes	No 1st day L Yes	M.Period	Medici Vhat K	Medica	ation	Allergie	How	w long?	-	ation P	rovid		Yes	1
	Current Med Pregnant Chronic Illness of BCG Vaccine	Yes Yes	No Me Probl	Yes laybe ems	No 1st day L Yes ge?;	M.Period	Medici	Medica / / ind? epatitis?	ation E	Allergie	How s: /	v long?	Hand Hep A	ation P	rovid	led	Yes	1
2	Current Med Pregnant Chronic Illness of	Yes or Immun	No Me Probl	Yes laybe ems What as	No 1st day L. Yes gee?;	M,Period No W	Medici	Medica / / ind? epatitis? ack (s) per da	ation El	Allergie DC: (Potent	How s: /	v long? /- ery Date) Type Number	Hand Hep A	ation P outs P Hep I	rovid	led	Yes	Jnk
R	Current Med Pregnant Chronic Illness of BCG Vaccine	Yes Yes	No Me Probl	Yes laybe ems What as	No 1st day L Yes ge?;	M,Period No W	Medici	Medica / / ind? epatitis?	ation El	Allergie DC: (Potent	How s: /	v long?  / ery Date)  Type  Number  How oft	Hand Hep A r of years:	ation Pouts PHep E	rovid	led	Yes	Jnk
i	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking	Yes Yes	No Mono Mono No	Yes laybe ems What as	No 1st day L. Yes gee?;	M.Period No W	Medici	Medica / / ind? epatitis? ack (s) per da	ation .	Allergie DC: (Potent	How s: /	v long? /- ery Date) Type Number	Hand Hep A r of years:	ation P outs P Hep E	rovid B E	led	yes	Jnk
1 5	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use	Yes Yes Yes	No Mo	Yes laybe ems What as	No 1st day L Yes ge?: ast use: ast use:	M.Period No W	Medici	Medica / ind? epatitis? eck (s) per de rug (s) of Cha	ation El	Allergie DC: (Potent Yes	Howes: // idal Deliv	Type Number How off	Hep A Hep A r of years:	ation Pouts PHep E	rovid B b	led Hep C	#yr#yr#yr	Unk
l s k	Current Med Pregnant Chronic lilness of BCG Vaccine Smoking IV Drug use Other Drug use	Yes Yes Yes Yes Yes Yes	No Mo No	Yes laybe ems What as Date of Is Date of Is	No 1st day L Yes ge?: ast use: ast use:	M.Period No W	Medici	Medica / / ind? epatitis? ack (s) per de rug (s) of Chy	ation El	Allergie DC: (Potent Yes	Howes: // idal Deliv	Type Number How off	Hand Hep A  r of years: en:	ation P outs P Hep E	Provide rovides to the control of th	led Hep C	yes	Jnk
i s k	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK	Yes Yes Yes Yes Yes Yes Yes Denies	No Mo No No No No dd Ye	Yes aybe ems What as Date of Is Date of Is	No  1st day L.  Yes  ge?: ast use: ast use: ast use: Multipl	M.Period No W	Medici What K H P D D D tners	Medica / ind? epatitis? eck (s) per de rug (s) of Cha	ation El	Allergie DC: (Potent Yes	Howes: // idal Deliv	Type Number How off	Hand Hep A r of years: een: Vt test?	ation P outs P Hep E	rovid B b	led Hep C	#yr#yr#yr	Unk
i s k	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei	Yes Yes Yes Yes Yes Yes Yes Denies	No Mo No	Yes aybe ems What as Date of Is Date of Is	No 1st day L Yes ge?: ast use: ast use: Multipl Yes N	M.Period No W	Medici What K H P D D D tners	Medica / / ind? epatitis? ack (s) per de rug (s) of Che rug (s) of Che Fights D# or SO#:	ation and a second a second and	Allergie DC: (Potent Yes	Howes: // lal Deliv No	v long?  / ery Date)  Type  Number  How off  How off  How off last Hi	Hand Hep A  r of years: een: een: V test?	How Muc	rovid B b	led Hep C	#yr#yr#yr	Unk
i s k	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei	Yes Yes Yes Yes Yes Yes Yes Denies	No Mo No	Yes laybe ems What ag Date of Is Date of Is S IVDU	No 1st day L Yes ge?: ast use: ast use: Multipl Yes N	M.Period No W e sex par	Medicion Med	Medica / / ind? epatitis? ack (s) per de rug (s) of Che rug (s) of Che Fights D# or SO#:	ation El	Allergie DC: (Potent Yes	Howes: // lal Deliv No	Type Number How off How off When	Hand Hep A r of years: een: Vt test?	How Muc	rovid B b	led Hep C	#yr#yr#yr	Unk
3	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei	Yes Yes Yes Yes Yes Yes Yes Denies	No Mo No	Yes laybe ems What as Date of Is Date of Is s IVDU	No 1st day L. Yes ge?: ast use: ast use: Multipl Yes N	M.Period  No W  e sex parto  HCV	Medicion Med	Medica / / ind? epatitis?  ack (s) per de rug (s) of Che ring (s) of Che Fights  D# or SO#:	ation El	Allergie DC: (Potent Yes	How No Date	Type Number How off How off When	Hand Hep A  of years: en: en: V test? e  Recomme	How Muc	h: Pos Whe	led Hep C	#yr #yr #yr Neg	Jnk rs
3	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ	Yes Yes Yes Yes Yes Yes Yes Denies	No Mo No	Yes  aybe ems  What ag  Date of Is  Date of Is  S IVDU  son	No  1st day L.  Yes  ge?: ast use: ast use: Multipl  Yes N  No	M.Period No W e sex pare O HCV Che	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provide:	ation El	Allergie DC: (Potent Yes   contact	Hox S: 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1 / 1	Viong?  Type Number How off How off How off When SLVHI	Hand Hep A  of years: en: en: V test? e  Recomme	How Muc How Muc How Muc Yes Yes	rovid  ro	led Hep C	#yr #yr #yr Neg	Unk
3	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ TB Reactor TB Convertor	Yes	No Mo No	Yes  What ag  Date of I:  Date of I:  Son  Yes  Yes  Yes	yes   ge?: ast use: ast use: ast use: Multipl Yes   No	M.Period  No W  e sex pare  o HCV  Che Spu	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provide:	ation El	Allergie DC: (Potent Yes  contact  rg Ca Yes Yes	How Signature Plants No	Viong?  Type Number How off How off When SLVHI Prior 1 Conta	Hand Hep A  r of years: en: V test? e  Recomme	How Muc How Muc How Muc Yes Yes	rovid 3 t	led Hep C	#yr #yr #yr Neg	Unk
i s k	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ	Yes	No Mo No	Yes  What ag  Date of I:  Date of I:  Son  Yes  Yes  Yes	yes   ge?: ast use: ast use: ast use: Multipl Yes   No	M.Period  No W  e sex pare  o HCV  Che Spu	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provider	ation El	Allergie DC: (Potent Yes  contact  rg Ca Yes Yes Yes Yes	How Signature Plants No	Viong?  Type Number How off How off When SLVHI Prior 1 Conta	Hand Hep A  r of years: en: V test? e  Recomme D Co-pay arnt films Iners provided	How Muc How Muc How Muc Yes Yes	rovid  ro	led Hep C	#yr #yr #yr Neg	Unk
RISKS	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ TB Reactor TB Convertor	Yes	No Mo No	Yes  What ag  Date of I:  Date of I:  Son  Yes  Yes  Yes	yes   ge?: ast use: ast use: ast use: Multipl Yes   No	M.Period  No W  e sex pare  o HCV  Che Spu	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provider	ation El	Allergie DC: (Potent Yes  contact  rg Ca Yes Yes Yes Yes	How Signature Plants No	Viong?  Type Number How off How off When SLVHI Prior 1 Conta	Hand Hep A  r of years: en: V test? e  Recomme D Co-pay arnt films Iners provided	How Muc How Muc How Muc Yes Yes	rovid  ro	led Hep C	#yr #yr #yr Neg	Jnk
i s k	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ TB Reactor TB Convertor	Yes	No Mo No	Yes  What ag  Date of I:  Date of I:  Son  Yes  Yes  Yes	yes   ge?: ast use: ast use: ast use: Multipl Yes   No	M.Period  No W  e sex pare  o HCV  Che Spu	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provider	ation El	Allergie DC: (Potent Yes  contact  rg Ca Yes Yes Yes Yes	How Signature Plants No	Viong?  Type Number How off How off When SLVHI Prior 1 Conta	Hand Hep A  r of years: en: V test? e  Recomme D Co-pay arnt films Iners provided	How Muc How Muc How Muc Yes Yes	rovid  ro	led Hep C	#yr #yr #yr Neg	Unk
3	Current Med Pregnant Chronic Illness of BCG Vaccine Smoking IV Drug use Other Drug use Alcohol use HIV RISK Circle risk History of bei Nurs Suspect activ TB Reactor TB Convertor	Yes	No Mo No	Yes  What ag  Date of I:  Date of I:  Son  Yes  Yes  Yes	yes   ge?: ast use: ast use: ast use: Multipl Yes   No	M.Period  No W  e sex pare  o HCV  Che Spu	Medicion Med	Medica  / / ind? epatitis? eck (s) per de rug (s) of Che rug (s) of Che rink (s) of Che Fights  D# or SO#:  N ray Planned other provider	ation El	Allergie DC: (Potent Yes  contact  rg Ca Yes Yes Yes Yes	How Signature Plants No	Viong?  Type Number How off How off When SLVHI Prior 1 Conta	Hand Hep A  r of years: en: V test? e  Recomme D Co-pay arnt films Iners provided	How Muc How Muc How Muc Yes Yes	rovid  ro	led Hep C	#yr #yr #yr Neg	Unk

Letter: from company to employees re suspected index patient w/testing date

[Company] [Address]
[Date]
[Employee] [Address] [City, State, Zip]
To all employees:
[Agency name] will conduct a tuberculosis (TB) screening program on [date and time]. The tuberculin skin test that will be given can determine whether or not a person has been exposed to tuberculosis.
[Agency name] has informed us that an individual at this company may possibly have tuberculosis. This is not a medical emergency. The affected employee is receiving medical treatment and will return to work only when no longer considered infectious. As a precautionary measure, we have asked [agency name] to screen employees who may have been exposed.
Persons found to have a positive TB skin test will be asked to have a follow-up chest x-ray to be sure that they do not have tuberculosis. These tests will be performed free of charge by the [agency name].
Whenever many people are tested, some are always found to have positive skin tests. This does not always mean that they were exposed in the workplace where the testing is being done. Overall, results of the investigation can help determine if TB infection was transmitted in this workplace, or at some other time and location.
If you have had a previously positive tuberculin skin test, please bring documentation of this. The health department [title of health worker] will counsel you about the need for any further testing which may be necessary.
You may go to your family doctor for the TB skin test. If you do, you will need to have the doctor fill out the form enclosed with this letter and return it to [agency name].
Thank you.
[Name] [Title of Employer/Supervisor]
ENC: 1

PLEASE RETURN THIS FORM BY FAX TO: PHN r	name and fax number
--	---------------------

Dear Doctor:

Please complete the following information regarding the TB skin testing of this patient and return this portion by fax as soon as possible.

Note: Testing by the Mantoux method is required and self-reading is not allowed. Because this patient is a contact to a person with communicable TB, **a reading of 5 mm or greater is considered positive**.

Patient's name:	
Address:	
Telephone no:	Date of Birth:
Mantoux Test:	
Date placed: Date read	: Results: mm
Follow-up medical evaluation:	
Chest x-ray date:	Results:normalabnormal
Medical evaluation date:	
Diagnosis:CaseSuspect	Reactor (latent infection, no disease)
Therapy:yesno	
If yes, medication:	Dose:
Date started:	
Address:	
Telephone number:	
Physician's signature	Date:

#### Letter: from LHD to employees re confirmed case w/testing date

#### [Date]

[Former Employee]
[Address]
[City, State, Zip]

#### Dear [Employee]:

Recently you may have been in contact with an individual who has active tuberculosis (TB). To protect your health, the [agency name] strongly recommends that you receive a TB skin test. For your convenience, the [agency name] will provide skin tests at your worksite. The test will be given on [date and time] and is free of charge. Test results will be read on [date and time].

This simple test is called a PPD skin test or "Mantoux" skin test. It indicates whether you have any TB germs in your body. The test involves a slight prick to the skin on your forearm. Most people experience very little or no pain or discomfort. After 48 to 72 hours, the [agency name] representative will look at your arm and determine if the test is negative or positive.

- You have a negative test result if there is little or no change to your skin on your arm around the test
  area. It means that at this time there is no evidence that you are infected with the germ that causes
  TB. If you have been exposed to a person with TB, it can take up to 8-10 weeks to develop a positive
  PPD skin test. Therefore you will need to be tested again in 8-10 weeks.
- 2. A *positive* test result shows as a small swelling on your arm around the test area. It means that the germ that causes TB is present in your body. You will need to have a chest x-ray to determine if the TB germ is active. A positive skin test *does not* mean that you have TB disease or can give TB to anyone else. Any needed follow-up will be provided by [agency name].

If you prefer, you may go to your family doctor for the TB skin test. In that case, have the doctor fill out the bottom portion of this letter and return it to [agency name] at the address at the top of this letter. You should have your doctor give you the test by [date].

Please read the attached fact sheet about TB. It will answer many of your questions. Just before the testing on [date and time], we will hold a meeting at your worksite to give you more information. In the meantime, if you have any questions, please call [agency name] at [phone number].

Sincerely,	
Name] Fitle	
Dear Doctor:	
Please complete the following information regardinmail or fax as soon as possible to [agency name, a	g the TB skin testing of this patient and return this portion by ddress, fax number].
Note: Testing by the Mantoux method is required a contact to a person with communicable TB, a readi	and self-reading is not allowed. Because this patient is a ng of 5 mm or greater is considered positive.
Name of patient:	
PPD: Date placed: Date read:	Resultsmm
Chest x-ray done: (circle) Yes/No f yes, CXR date: CXR results: WNL NH start date:	(within normal limits) / other:
Physician's name and phone number:	

Date
Dear Parents, Staff, and Students:
A student at [Name of school] has been diagnosed with active tuberculosis disease. This student is under the care of a physician and is being treated. The [State Health

student is under the care of a physician and is being treated. The [State Health Department] and [Name of Local Health Department]s have reviewed this case and necessary actions are being taken for the protection of every student, staff, and faculty member.

School Letter: from LHD to All Parents/Staff

At the present time this student is no longer infectious; however limited exposure may have occurred in the recent past. We will be conducting testing of those whom we feel are at greatest risk of exposure. Those specific individuals will be contacted directly by the school, indicating dates and times of the testing.

Although this disease is worrisome, it is treatable and curable. Tuberculosis is not easily transmitted, and the likelihood of infection is quite low. If you have any questions, please call [LHD phone number].

Sincerely,

Local Health Officer

School Letter: from LHD to Staff/Parents of Students with Exposure w/Test Dates
Date
Dear Parents, Faculty, and Staff:
We have identified you or your student as someone who may have been exposed to tuberculosis (TB). TB is spread from person to person through the air. When a person with TB coughs, sneezes, speaks or sings, respiratory droplets are expelled into the air. Depending on the environment, these tiny particles can remain suspended in the air for several hours, and can be inhaled.
Persons at the highest risk of becoming infected with tuberculosis are close contacts. These are persons who have had prolonged or frequent contact with a person who has infectious tuberculosis.
At this time, we are asking you or your student to have a PPD skin test done. Nurses and staff from the [Local Health Department] will place the test on [date] and [date] beginning at [time] at [venue]. These tests will need to be read in 48-72 hours after placement. This test consists of a small injection on the forearm, just under the skin. If you or your student misses these testing times, we will contact you directly.
In order to administer this test we do need permission from a parent or guardian of your child. Please sign the brief consent statement below.
I hereby authorize [Local Health Department] to administer a PPD skin test to my child for evaluation of possible exposure to tuberculosis. <u>Please bring this letter back on the testing dates.</u>
Child's name (please print)  Parent/Guardian signature
If you have any questions regarding this matter, please contact [name] at [phone number].
Health Officer

# School Letter: from LHD to Staff/Parents of Students w/Exposure – 2nd TST date

Date	
Dear Parents, Faculty, and Staff:	
In [month], you or your student was identified as sort to tuberculosis (TB). At that time, you or your stude were positive were contacted. We now need to compete those individuals who initially tested negative.	nt was tested for TB, and those who
At this time, we are asking you or your student have and staff from the [local health department] will plac [time] at [venue]. These tests will need to be read 48 return on [date] to read those tests and place tests on testing. We will then return on [date] to read those t date]. If you or your student misses these testing times.	the test on [date] beginning at 3-72 hours after placement, so we will those who missed the first day of ested on [day of week of second test
In order to administer this test we do need permissio child. Please sign the brief consent statement below	
I hereby authorize [Local Health Department] to child for evaluation of possible exposure to tubero back on the testing dates.	
Child's name (please print)	Parent/Guardian signature
If you have any questions regarding this matter, plea	se contact [name] at [phone number].
Health Officer	

# PUBLIC HEALTH INCIDENT

#### [your agency name, address, phone number]

Internal Notification Event: Case No.: Date & Time of Event: Site of Event: Human Exposure (describe): Lead Public Health Agency: □ Local (specify): \_\_\_\_\_ □ State Other Agencies Involved (check all that apply): □ CDC □ EMS □ Local School District Criminal Justice Local Police □ Others (specify): Potential Media Interest (circle): [highly likely] ---- 5 4 3 2 1 ---- [unlikely]

Date & Time of Notification: Investigation Coordinator:

Notification Completed by:

Phone/Fax:

#### **EMPLOYER ACKNOWLEDGMENT OF CONFIDENTIALITY**

I,	as an agent for			
name	company			
in the capacity of	and having been contacted by			
job title				
of	have been health dept./clinic name			
case manager	health dept./clinic name			
informed that one of our employees,	(Case #) name			
has been diagnosed with active tuberculo	osis and has possibly exposed other staff.			
I understand that medical informat	tion is confidential and that the employee named			
above may not be revealed as the source	e of the TB exposure. I also acknowledge that the			
diagnosis of tuberculosis is covered unde	er the ADA (Americans with Disabilities Act) and			
any discrimination or retribution towards	the employee is unlawful.			
Signature	Signature of witness (Case Manager)			
Print name	Print name			
 Date				

# **CHEST X-RAY LOG**

Health District	 
Case No	

Date of x-ray	Name (Last, first, middle initial)	Age	Sex	PPD test	Former Film No.	History	Film No.

# **CONTACT INVESTIGATION SUMMARY**


[your agency name, address, phone number]

40.	Coop No				
ate:	Case No:				
te name:					
esting dates: Initial:	_ 3-mo Follow-	up:			
	Contacts	Non-contacts	Total		
	N (%)	N (%)	N (%)		
Screened	(***)	(**)	(/		
PPD-negative					
PPD-positive					
CXR within normal limits					
CXR abnormal					
CXR not done					
Previous positive PPD					
CXR recommended					
CXR within normal limits					
CXR abnormal					
CXR not done					
Percent positive (new & plus previous positive)					
Foreign-born					
U.Sborn					
Possible converters (identified at 3-mo F/U)					
1 OSSIDIO COTTOTO (Identified at 5-IIIo 170)					
Not screened					
Not tested					
PPD placed/not read					
Total					
omments / special considerations:					

# Concentric Circle Approach to Contact Investigation for Tuberculosis

#### First concentric circle

(high-risk contacts and close contacts)



#### HIGH PRIORITY CONTACTS FOR TESTING

	Contacts Most Likely to Be Infected (Close Contacts)		Contacts at High Risk Of Developing TB Disease Once Infected
•	Contacts exposed to patients with a high degree of infectiousness based on the following factors:		ontacts who are young children less than 4 ears of age
	o Laryngeal or pulmonary TB		Contacts with any of these conditions:
	o AFB sputum smear positive		HIV infection
	o Cavitary disease on chest x-ray		Injection with illicit drugs
	o Cough		Diabetes mellitus
	o Positive culture for Mycobacterium tuberculosis		Silicosis
•	Contacts exposed to patients in:		Prolonged corticosteroid therapy
	o Small or crowded rooms		Immunosuppressive therapy
	o Areas that are poorly ventilated		Certain types of cancer
	o Areas without air-cleaning systems		Severe kidney disease
•	Contacts who:	c	Certain intestinal conditions
	o Frequently spend a lot of time with the patient		Low body weight (10% or more below ideal)
	o Have been physically close to the patient		

## WORKSITE CONTACT INVESTIGATION – ACTION PLAN

STEP	ACTIVITY/DESCRIPTION	RESPONSIBLE PERSON	DUE DATE	DATE COMPLETED
STEP 1	MEDICAL RECORDS REVIEW AND PATIENT INTE		DAIL	OOMII EETED
1-A	Review the index case's medical information to			
	confirm diagnosis of sputum AFB-smear			
	positive pulmonary and/or laryngeal TB.			
1-B	Interview the index case.			
4.0	Fatablish the manifed of infantianness			
1-C	Establish the period of infectiousness.			
1-D	Determine if there are factors present at			
	worksite that enhance likelihood of TB			
	transmission.			
STEP 2	ASSESS NEED FOR WCI AND DETERMINE ITS SC	OPE		
2-A	Decide if a WCI is necessary.			
2-B	Review current policies regarding confidentiality.			
2-C	Re-interview index case, focusing on worksite;;			
	request permission to disclose her/her identity.			
STEP 3	ESTABLISH COMMUNICATION WITH THE WORKS	SITE		
3-A	Contact the worksite.			
3-B	Establish who will be the employer liaison.			
-	' '			
3-C	Provide educational information re: TB and			
	contact investigations to the employer			
3-D	representative and other key staff.  Determine who will pay for the different			
3-0	investigation costs.			
3-E	Ensure that the employer understands the need			
3-L	for confidentiality and other legal concerns.			
3-F	Answer any questions re: the index case that			
	the employer may have.			
3-G	If applicable, establish media contacts at			
	UDOH, the LHD, and at the worksite.			
STEP 4	DEVELOP AN ACTION PLAN			
4-A	Verify information provided by the index case			
	with the employer			
4-B	Prepare a written action plan.			
4-C	If applicable, document the need and			
	arrangements for the screening in a letter to the			
	company.			
STEP 5	CONDUCT AN ENVIRONMENTAL EVALUATION O	F THE WORKSITE		
5-A	Determine where the index case spent time.			
5-B	Evaluate the spaces to determine how			
	conducive they are to TB transmission.			<u> </u>
STEP 6	DEVELOP THE CONTACT LIST			
6-A	Identify individuals with whom the index case			
	had contact.			
6-B	Determine which employees are high priority vs			
6.0	low priority contacts.			
6-C	Prepare a roster of contacts.			<u> </u>
6-D	Identify contacts who face barriers to			
	healthcare.			
STEP 7	ARRANGE FOR FOLLOW-UP X-RAYS	ı		
7-A	Identify a resource for chest x-rays (CXRs).			
7-B	Determine who will pay for the CXRs.			
STEP 8	ARRANGE FOR SCREENINGS AND TSTS			
8-A	Determine with the employer a screening site.			
8-B	ON-SITE SCREENING: Select a suitable space,			
	date, and time for the screenings.			
8-C	OFF-SITE SCREENING: Determine where			
	employees will be referred for testing.			

Set a target date for the completion of the first			
	DEODONIOIDI E	5115	5475
ACTIVITY/DESCRIPTION			DATE
		DATE	COMPLETED
	TB		-
would be appropriate.			
With the employer, plan and conduct the			
materials and answering employees' questions.			
	EENING SESSION(S)		
ON-SITE TESTING: Conduct initial screening			
activities.			
OFF-SITE TESTING: Await test results.			
Arrange for and obtain CXRs.			
Refer for bacteriology evaluation and			
consideration for treatment.			
Be diligent in follow-up to make sure that			
referred individuals are properly diagnosed and			
treated.			
DECIDE WHETHER TO EXPAND OR LIMIT THE WO	)I		
Evaluate initial screening results to determine			
whether to expand the WCI.			
Consult with Local Health supervisor/officer.			
CONDUCT A THREE-MONTH FOLLOW-UP SCREE	NING-		•
Notify contact who need to be re-tested.			
Make a list of contacts who require follow-up			
testing and set follow-up testing date.			
Conduct follow-up testing.			
Arrange follow-up CXRs as necessary.			
REPORT THE INITIAL RESULTS			1
the employer.			
	round of screening.  ACTIVITY/DESCRIPTION  EDUCATE THE COMPANY'S EMPLOYEES ABOUT Assess what kinds of educational materials would be appropriate. With the employer, plan and conduct the educational session. If an educational session is not feasible, make alternative arrangements for distributing materials and answering employees' questions. NOTIFY CONTACTS ABOUT AND CONDUCT SCRI Notify affected employees regarding their exposure and need for screening. ON-SITE TESTING: Conduct initial screening activities. OFF-SITE TESTING: Await test results.  Arrange for and obtain CXRs.  Refer for bacteriology evaluation and consideration for treatment. Be diligent in follow-up to make sure that referred individuals are properly diagnosed and treated.  DECIDE WHETHER TO EXPAND OR LIMIT THE WC Evaluate initial screening results to determine whether to expand the WCI. Consult with Local Health supervisor/officer.  CONDUCT A THREE-MONTH FOLLOW-UP SCREE Notify contact who need to be re-tested.  Make a list of contacts who require follow-up testing and set follow-up testing date. Conduct follow-up CXRs as necessary.  REPORT THE INITIAL RESULTS  Prepare an aggregate report and present it to	ACTIVITY/DESCRIPTION  RESPONSIBLE PERSON  BUCATE THE COMPANY'S EMPLOYEES ABOUT TB  Assess what kinds of educational materials would be appropriate.  With the employer, plan and conduct the educational session.  If an educational session is not feasible, make alternative arrangements for distributing materials and answering employees' questions.  NOTIFY CONTACTS ABOUT AND CONDUCT SCREENING SESSION(S)  Notify affected employees regarding their exposure and need for screening.  ON-SITE TESTING: Conduct initial screening activities.  OFF-SITE TESTING: Await test results.  Arrange for and obtain CXRs.  Refer for bacteriology evaluation and consideration for treatment.  Be diligent in follow-up to make sure that referred individuals are properly diagnosed and treated.  DECIDE WHETHER TO EXPAND OR LIMIT THE WCI  Evaluate initial screening results to determine whether to expand the WCI.  Consult with Local Health supervisor/officer.  CONDUCT A THREE-MONTH FOLLOW-UP SCREENING- Notify contact who need to be re-tested.  Make a list of contacts who require follow-up testing and set follow-up testing date.  Conduct follow-up testing.  Arrange follow-up CXRs as necessary.  REPORT THE INITIAL RESULTS  Prepare an aggregate report and present it to	RESPONSIBLE PERSON  ACTIVITY/DESCRIPTION  RESPONSIBLE PERSON  DATE  DUE  DATE  EDUCATE THE COMPANY'S EMPLOYEES ABOUT TB  Assess what kinds of educational materials would be appropriate.  With the employer, plan and conduct the educational session.  If an educational session is not feasible, make alternative arrangements for distributing materials and answering employees' questions.  NOTIFY CONTACTS ABOUT AND CONDUCT SCREENING SESSION(S)  Notify affected employees regarding their exposure and need for screening.  ON-SITE TESTING: Conduct initial screening activities.  OFF-SITE TESTING: Await test results.  Arrange for and obtain CXRs.  Refer for bacteriology evaluation and consideration for treatment.  Be diligent in follow-up to make sure that referred individuals are properly diagnosed and treated.  DECIDE WHETHER TO EXPAND OR LIMIT THE WCI  Evaluate initial screening results to determine whether to expand the WCI.  Consult with Local Health supervisor/officer.  CONDUCT A THREE-MONTH FOLLOW-UP SCREENING-  Notify contact who need to be re-tested.  Make a list of contacts who require follow-up testing and set follow-up testing and set follow-up testing.  Arrange follow-up CXRs as necessary.  REPORT THE INITIAL RESULTS  Prepare an aggregate report and present it to